Korro Bio Inc

Investor alert: Lynx1 Capital’s recent buy‑in signals confidence in Korro Bio’s rare‑disease RNA‑therapy pipeline and a potential upside as the company edges toward phase‑II trials.

Insider buying surges at Korro Bio, signaling confidence in its RNA‑editing platform and a potential upside beyond the current $11.5 price.

Insider buying spurs optimism at Korro Bio: COO & execs lock in $1.2 M in zero‑cost options, signaling confidence in RNA‑therapy pipeline and upside potential.